Grail (GRAL) is making its Galleri multicancer early detection test directly available to physicians in the US through its collaboration with Quest Diagnostics (DGX), the companies said Wednesday.
The companies said the test can now be ordered from Grail through Quest's connectivity system, helping streamline the process of ordering for physicians.
The integration of Grail's test into Quest's connectivity system will also increase availability by making the test accessible to patients at any Quest patient access point, the companies said.
Financial details of the collaboration weren't provided.
Price: 33.01, Change: -0.14, Percent Change: -0.42
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.